Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 26,700 shares, a growth of 641.7% from the January 31st total of 3,600 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average daily volume of 1,040,000 shares, the short-interest ratio is currently 0.0 days.

Pasithea Therapeutics Stock Down 5.4 %

Shares of NASDAQ:KTTA traded down $0.07 during midday trading on Thursday, reaching $1.22. The company had a trading volume of 36,135 shares, compared to its average volume of 1,739,519. The stock’s fifty day moving average price is $2.28 and its 200-day moving average price is $3.40. Pasithea Therapeutics has a one year low of $1.12 and a one year high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.